Table 1 Patient Baseline Demographics
Baseline characteristics | Total study population (N = 1103) | AR with no asthma (n = 836) | AR with asthma (n = 267) |
|---|---|---|---|
Gender, n (%) | |||
Male | 474 (43.0) | 355 (42.5) | 119 (44.6) |
Female | 624 (56.6) | 478 (57.2) | 146 (54.7) |
Missing | 5 (0.5) | 3 (0.4) | 2 (0.8) |
Age, n (%) | |||
12–17 years | 82 (7.4) | 67 (8.0) | 15 (5.6) |
18–65 years | 937 (85.0) | 711 (85.0) | 226 (84.6) |
> 65 years | 84 (7.6) | 58 (6.9) | 26 (9.7) |
Allergic sensitization (number of allergens), n (%) | |||
1 | 178 (16.1) | 152 (18.2) | 26 (9.7) |
2–5 | 570 (51.7) | 428 (51.2) | 142 (53.2) |
> 5 | 176 (16.0) | 96 (11.5) | 80 (30.0) |
Unknown | 179 (16.2) | 160 (19.1) | 19 (7.1) |
Type of AR, n (%) | |||
Perennial only | 120 (10.9) | 102 (12.2) | 18 (6.7) |
Seasonal only | 435 (39.4) | 354 (42.3) | 81 (30.3) |
Perennial and seasonal | 444 (40.3) | 285 (34.1) | 159 (59.6) |
Missing | 104 (9.4) | 95 (11.4) | 9 (3.4) |
Allergic comorbidities, n (%) | |||
Asthma | 267 (24.2) | 0 (0) | 267 (100) |
Dermatitis/eczema | 127 (11.5) | 90 (10.8) | 37 (13.9) |
Food allergy/allergies | 109 (9.9) | 81 (9.7) | 28 (10.5) |
Severe allergic reactions | 30 (2.7) | 18 (2.2) | 12 (4.5) |
None | 593 (53.8) | 593 (70.9) | 0 |
Missing | 89 (8.1) | 89 (10.6) | 0 |
Baseline AR-VAS scores, mean (SD) | |||
AR-VAS scores | 73.2 (13.4) | 72.8 (13.4) | 74.1 (13.5) |
Previous symptomatic AR treatments since last year, n (%) | |||
Oral, nonsedating H1-antihistamine | 506 (45.9) | ||
Intranasal corticosteroid | 471 (42.7) | ||
Intranasal decongestant | 191 (17.3) | ||
Intranasal H1-antihistamine | 177 (16.0) | ||
Oral, first-generation H1-antihistamine | 162 (14.7) | ||
Ocular H1-antihistamine | 133 (12.1) | ||
Oral or nebulized corticosteroid | 99 (9.0) | ||
Intranasal mast cell stabilizer | 62 (5.6) | ||
Oral leukotriene antagonist | 50 (4.5) | ||
Ocular mast cell stabilizer | 42 (3.8) | ||
Oral decongestant | 26 (2.4) | ||
Other | 54 (4.9) | ||
Unknown | 24 (2.2) | ||
None | 164 (14.9) | ||